Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1635 1637 1671 1682
This examiner grants 52% of resolved cases
Christina L Tran is an examiner in Tech Center 1600, Art Unit 1600. The examiner has 62 resolved cases. The data shows an allowance rate of 51.6 percent and an interview lift of 48.2 percent. The median days to allowance for these cases is 1453.
The 48.2 percent interview lift is a significant figure when compared to the 51.6 percent base allowance rate. This indicates that conducting an interview is a method for increasing the likelihood of an allowance. The 1453 day median pendency is the timeframe applicants can expect when navigating the resolved cases handled by this examiner in Art Unit 1600. Practitioners can consider how these metrics influence the overall prosecution timeline.
With 62 resolved cases, the examiner's statistics provide a view of the prosecution landscape. Practitioners can use the 51.6 percent allowance rate to assess the probability of a grant. The 48.2 percent lift and the Tech Center 1600 environment are factors for prosecution strategy. These data points help in setting expectations for clients.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17621029 | STRUCTURALLY DEFINED SIRNA-DUAL VARIABLE DOMAIN IMMUNOGLOBULIN CONJUGATES | Non-Final OA | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED |
| 17601522 | AIM2 INHIBITORS AND USES THEREOF | Final Rejection | University of Massachusetts |
| 17044195 | Compositions Comprising Immune System Activators and Method of Using Same | Final Rejection | The Trustees of Princeton University |
| 17266502 | PARN AS A BIOMARKER AND THERAPEUTIC TARGET | Non-Final OA | The Regents of the University of Colorado, a body corporate |
| 17800371 | AAV-Mediated Targeting of MIRNA in the Treatment of X-Linked Disorders | Final Rejection | UNIVERSITY OF VIRGINIA PATENT FOUNDATION |
| 18251514 | PRECISE GENOME DELETION AND REPLACEMENT METHOD BASED ON PRIME EDITING | Non-Final OA | University of Washington |
| 18276848 | RNA Trans-Splicing Molecule | Non-Final OA | Cambridge Enterprise Limited |
| 17794673 | METHODS AND COMPOSITIONS FOR GENERATING TYPE 1 VESTIBULAR HAIR CELLS | Non-Final OA | Decibel Therapeutics, Inc. |
| 17769255 | GENE THERAPY FOR ALZHEIMER'S DISEASE | Final Rejection | Cornell University |
| 18243133 | GLYCOGEN SYNTHASE KINASE 3 ALPHA (GSK3 ALPHA) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18324191 | METHODS AND COMPOSITIONS FOR INHIBITION OF HAO1 (HYDROXYACID OXIDASE 1 (GLYCOLATE OXIDASE)) GENE EXPRESSION | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 18015202 | Circular siRNAs | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17974596 | APOLIPOPROTEIN E (APOE) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17611761 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 18050017 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Non-Final OA | LONZA SALES AG |
| 17635315 | EXTRACELLULAR VESICLES WITH STAT3-ANTISENSE OLIGONUCLEOTIDES | Final Rejection | LONZA SALES AG |
| 17635322 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Final Rejection | LONZA SALES AG |
| 18294048 | AQP1 GENE THERAPY TO PREVENT RADIATION INDUCED SALIVARY HYPOFUNCTION | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18570938 | Methods and Compositions for ADAR-Mediated Editing | Non-Final OA | KORRO BIO, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy